Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor

Journal of Immunology

Volumn 164, Issue 7, 2000, Pages 3902-3912

  Baxevanis, Constantin N ^a   Voutsas, Ioannis F ^a   Tsitsilonis, Ourania E ^a   Gritzapis, Angelos D ^a   Sotiriadou, Roula ^a   Papamichail, Michael ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 7; SYNTHETIC PEPTIDE;

ADOPTIVE IMMUNOTHERAPY; ADVANCED CANCER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; MALE; METASTASIS; MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

EID: 0034176817     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.7.3902     Document Type: Article

References (53)

1. + T cell receptor-αβ phenotypes generated in CD8-depleted C57BL/6 mice. J. Immunol. 150:4900.
2. k negative mouse leukemia cell line K36.16. Immunology 72:213.
3. Ostrand-Rosenherg, S., A. Thakur, and U. Clements. 1990. Rejection of mouse sarcoma cells after transfection with MHC class II genes. J. Immunol. 144:4068.
4. Chen, P., and H. Aanathaswamy. 1993. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2. J. Immunol. 151:244.
5. + T cells in cancer immunotherapy. Curr. Opin. Immunol. 6:741.
6. + T cell responses on antitumor immunity. Curr. Opin. Immunol. 10:588.
7. Halder, T., G. Pawelec, A. F. Kirkin, J. Zeuthen, H. E. Meyer, L. Kun, and H. Kalbacher. 1997. Isolation of a novel HLA-DR restricted potential tumor-associated antigen from the melanoma cell line FM3. Cancer Res. 57:3238.
8. Wen, Y. J., and S. H. Lim. 1997. T cells recognize the VH complementarity region 3 of the idiotypic protein of B cell non-Hodgkin's lymphoma. Eur. J. Immunol. 27:1043.
9. + T lymphocytes respond to dendritic cells pulsed with b3α2 peptide and antigen presenting cells exposed to b3α2 containing cell lysates. Blood 90:290.
10. De Gruijl, T. D., H. J. Bontkes, J. M. M. Walboomers, M. J. Stukart, F. S. Doekhie, A. J. Remmink, T. J. M. Helmerhorst, R. H. M. Verheijen, M. F. Duggankeen, P. L. Stern, et al. 1998. Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia. Cancer Res. 58:1583.
11. 12Vαl-dependent nested epitopes present within the vaccine peptide and kill autologous tumor cells carrying this mutation. Int. J. Cancer 72:784.
12. ras peptide vaccination. Br. J. Cancer 74:1828.
13. + T-cell immunity to mutated ras protein in pancreatic and colon cancer patients. Cancer Res. 55:2984.
14. + T-helper and a T-killer cell. Nature 393:474.
15. Bennett, S. R. M., F. R. Carbone, F. Karamalis, R. A. Flavell, J. F. A.-P. Miller, and W. R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393:478.
16. Qin, Z., G. Richter, T. Schueler, S. Ibe, X. Cao, and T. Blankenstein. 1998. B cells inhibit induction of T cell-dependent tumor immunity. Nat. Med. 4:627.
17. Ossendorp, F., E. Mengede, M. Camps, R. Filius, and J. M. Melief. 1998. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 187:603.
18. Greenberg, P. D. 1991. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49:281.
19. Klarnet, J. P., D. E. Kern, K. Okumm, C. Holt, F. Lilly, and D. Greenberg. 1989. FBL-reactive CD8 cytotoxic and CD4 helper T cells recognize distinct Friend murine leukemia virus-encoded antigens. J. Exp. Med. 169:457.
20. Schoenberger, S.P., R. E. M. Toes, E. I. H. van der Voort, R. Offringa, and C. J. M. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480.
21. Baxevanis, C. N., G. V. Z. Dedoussis, N. G. Papadopoulos, I. Missitzis, G. P. Stathopoulos, and M. Papamichail. 1994 Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Cancer 74:1275.
22. + effectors. Br. J. Cancer 70:625.
23. Nair, S. K., D. Bockzowski, D. Snyder, and E. Gilboa. 1997. Antigen-presenting cells pulsed with unfractionated tumor derived peptides are potent tumor vaccines. Eur. J. Immunol. 27:589.
24. Brossart, B., G. Stuhler, T. Flad, S. Stevanovic, H.-G. Rammensee, L. Kanz, and W. Brugger. 1998. HER-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res. 58:732.
25. Fisk, B., T. L. Blevins, J. T. Wharton, and C. G. Ioannides. 1995. Identification of an immunodominant peptide of HER-2/neu-proto-oncogene recognized by ovarian tumor specific CTL lines. J. Exp. Med. 181:2709.
26. Koch, F., U. Stanzl, P. Jennwein, K. Janke, C. Heufler, E. Kampgen, N. Ramani, and G. Schuler. 1996. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and down regulation by IL-10. J. Exp. Med. 184:741.
27. Cella, M., D. Scheidegger, K. Palmer-Lehman, P. Lane, A. Lanzavecchia, and G. Alber. 1996. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184:747.
28. + T cells: modulation by interleukin-4 and interleukin-12. Eur. J. Immunol. 26:571.
29. Jung, T., U. Schauer, C. Rieger, K. Wagner, K. Einsle, C. Neumann, and C. Heusser. 1995. Interleukin-4 and interleukin-5 are rarely co-expressed by human T-cells. Eur. J. Immunol. 25:2413.
30. Peoples, G. E., P. S. Goedegebuure, R. Smith, D. C. Linehan, I. Yoshino, and T. J. Eberlein. 1995. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc. Natl. Acad. Sci. USA 92: 432.
31. Robins, P. F., and Y. Kawakami. 1996. Human tumor antigens recognized by T cells. Curr. Opin. Immunol. 8:628.
32. Kawashima, I., V. Tsai, S. Southwood, K. Takesako, A. Sette, and E. Celis. 1999. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization by peptide-pulsed dendritic cells. Cancer Res. 59:431.
33. Kawashima, I., V. Tsai, S. Southwood, E. Celis, and A. Sette. 1998. Identification of gp100-derived, melanoma-specific cytotoxic T lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells. Int. J. Cancer 78:518.
34. Castelli, C., P. Tarsini, A. Mazzocchi, F. Rim, L. Rivoltini, F. Ravagnani, F. Gallino, F. Belli, and G. Parmiani. 1999. Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens. J. Immunol. 162:1739.
35. + T cells recognize non-mutated HLA-DR-restricted tyrosinase epitopes. J. Exp. Med. 183: 1965.
36. Pawelec, G., H. Max, T. Halder, O. Bruserud, A. Merl, P. da Silva, and H. Kalbacher. 1996. BLR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. Blood 88:2118.
37. + T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cell. Int. J. Cancer 58:69.
38. + T cells. J. Exp. Med. 189:757.
39. + cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J. Exp. Med. 189:871.
40. + T lymphocytes against tumor melanoma: evidence for a shared melanoma antigen presented by HLA-DR15. J. Immunol. 154:772.
41. 13Gly→Asp mutation is recognized by HLA-DQ7 restricted T cells in a patient with colorectal cancer: modifying effect of DQ7 on established cancers harbouring this mutation? Int. J. Cancer 58:506.
42. Mackey, M. F., J. R. Gunn, C. Maliszewski, H. Kitutani, R. J. Noelle, and R. J. Barth, Jr. 1998. Dendritic cells require maturation via CD40 to penetrate protective anti-tumor immunity. J. Immunol. 161:2094.
43. Tsai, V., I. Kawashima, E. Keogh, K. Daly, A. Sette, and E. Celis. 1998. In vitro immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells. Crit. Rev. Immunol. 18:65.
44. Brichard, V., A. vanPel, T. Woelfel, C. Woelfel, E. de Plaen, B. Lethe, P. Coulie, and T. Boon. 1993. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178: 489.
45. Schichijo, S., M. Nakao, Y. Imai, H. Takasu, M. Kawamoto, F. Niiya, D. Yang, Y. Toh, H. Yamana, and K. Itoh. 1998. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J. Exp. Med. 187:277.
46. Baxevanis, C. N., and M. Papamichail. 1994. Characterization of the anti-tumor immune response in human cancers and strategies for immunotherapy. Crit. Rev. Oncol. Hematol. 16:157.
47. Baxevanis, C. N., G. V. Z. Dedoussis, N. G. Papadopoulos, I. Missitzis, C. Beroukas, G. P. Stathopoulos, and M. Papamichail. 1995. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor. Cancer 76:1253.
48. + cytotoxic T lymphocyte mediated lysis. J. Immunol. 150:4303.
49. Lee, R. K., J. Spielman, D. Y. Zhao, K. J. Olsen, and E. R. Podack. 1996. Perforin,Fαs ligand and tumor necrosis factor are the major cytotoxic molecules used by lymphokine activated killer cells. J. Immunol. 157:1914.
50. Baxevanis, C. N., M. L. Tsiatas, N. T. Cacoullos, G. Spanakos, C. Liacos, I. Missitzis, S. I. Papadhimitriou, and M. Papamichail. 1997. Induction of antitumor lymphocytes in cancer patients after brief exposure to supernatants from cultures of anti-CD3-stimulated allogeneic lymphocytes. Br. J. Cancer 76:1072.
51. Rongcun, Y., F. Salazar-Onfray, J. Charo, K.-I. Malmberg, K. Errin, H. Maes, K. Kono, C. Hising, M. Petersson, O. Larsson, et al. 1999. Identification of new HER-2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J. Immunol. 163:1037.
52. + CTL in vivo with peptide vaccine constructs. J. Immunol. 151:549.
53. + T cells in the antitumor immune response. J. Exp. Med. 188:2357.